Description:TCC,Human,mAbaE11,immunoassayantibody

MonoclonalantibodyaE11reactswithaC9neoantigenoftheterminalcomplementcomplex(TCC).ThethreedistinctactivationpathwaysofcomplementconvergewiththeformationofaC5convertase.ThecleavageofC5bythisconvertaseinitiatesthelyticorterminalpathway.Incontrasttotheactivationpathways,whichrequireenzymaticcleavageforactivation,theterminalpathwayreliesonconformationalchangesinducedbybinding.BindingofC6facilitatesbindingofC7whichalterstheconformationofthecomplex.AfterbindingofC8,avariablenumberofC9moleculesassociatewiththeC5b678complex,whichisalsotermed-theterminalcomplementcomplex(TCC).TheformationofTCCcauseslysisofcellsorcantriggeravarietyofcellularmetabolicpathwaysresultinginthesynthesisandreleaseofinflammatorymediators.TheTCCcontainsneoantigensthatareabsentfromtheindividualnativecomponents.-C9neoantigensarepresentbothinthemembrane-bound(MAC)andthefluid-phase(SC5b-9)complex.TCCispresentinnormalhumanplasmaandincreasedinpatientswithcomplementactivation.

Specifications:

CatalognumberHM2167-IA
ProducttypeMonoclonalantibodies
Quantity0.5mg
Formulation0.5mgof0.2μmfilteredproteinGpurifiedantibodysolutioninPBSwithaconcentrationofatleast0.5mg/ml(exactconcentrationisindicatedonthelabel).
ApplicationFlowcytometry,Frozensections,Functionalstudies,Immunoassays,Immunofluorescence,Paraffinsections
ApplicationNotesFS:AntibodyaE11inhibitsplateletactivationbyantiphospholipidantibodyserum.(Ref.5).
IF:Cryosectionsof10μmweredried,fixedinacetoneat4°Cfor10min,driedandblockedfor20minwithPBSA.
UseDilutionstobeuseddependondetectionsystemapplied.Itisrecommendedthatuserstestthereagentanddeterminetheirownoptimaldilutions.Thetypicalstartingworkingdilutionis1:50.
IsotypeMouseIgG2a
SpeciesHuman
CrossreactivityHorse-Yes,Pig-Yes
AliasTerminalcomplementcomplex,MACcomplex,complementmembraneattackcomplex,sC5b-9complex.
PositiveControlMucosafrompatientswithH.Pylori.
References1.Mollnes,Tetal;Quantificationoftheterminalcomplementcomplexinhumanplasmabyanenzyme-linkedimmunosorbentassaybasedonmonoclonalantibodiesagainstaneoantigenofthecomplex.ScandJImmunol1985,22:197
2.Mollnes,Tetal;Monoclonalantibodiesrecognizinganeoantigenofpoly(C9)detectthehumanterminalcomplementcomplexintissueandplasma.ScandJImmunol1985,22:183
3.Pettersen,Hetal;HumanalveolarmacrophagessynthesizeactivecomplementcomponentsC6,C7,andC8invitro.ScandJImmunol1987,25:567
4.Berstad,Aetal;EpitheliumrelateddepositionofactivatedcomplementinHelicobacterpyloriassociatedgastritis.Gut1997,40:196
5.Stewart,Metal.Antiphospholipidantibody-dependentC5b-9formation.BJH1997,96:451
6.Meuwissen,Metal.ColocalisationofintraplauqCreactiveprotein,complement,oxidisedlowdensitylipoprotein,andmacrophagesinstableandunstableanginaandacutemyocardialinfarction.JClinPath2005,59:126
StorageandstabilityProductshouldbestoredat4°C.Underrecommendedstorageconditions,productisstableforatleastoneyear.Theexactexpirydateisindicatedonthelabel.
PrecautionsForresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandfederalrulesintheuseofthisproduct.HycultBiotechisnotresponsibleforanypatentinfringementsthatmightresultfromtheuseorderivationofthisproduct.
DiseaseInfectiousdiseases,Nephrology